
Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

